Other Species / Isoforms
  CDV-3 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

  HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
T4-p
____MAEtEERsLDN
0 3
CDV-3 (human) ____MAEtEERsLDN T4-p
CDV-3 iso2 (human) ____MAETEERSLDN T4
CDV-3 (mouse) ____MAEtEERsLDN T4-p
CDV-3 (rat) ____MAETEERsLDN T4
S8-p
MAEtEERsLDNFFAk
Upstream
0 17
Treatment
  • ischemia
CDV-3 (human) MAEtEERsLDNFFAk S8-p
CDV-3 iso2 (human) MAETEERSLDNFFAK S8
CDV-3 (mouse) MAEtEERsLDNFFAK S8-p
CDV-3 (rat) MAETEERsLDNFFAk S8-p
K15-ac
sLDNFFAkRDKKKKK
Upstream
0 4
Treatment
  • MS275
CDV-3 (human) sLDNFFAkRDKKKKK K15-ac
CDV-3 iso2 (human) SLDNFFAKRDKKKKK K15
CDV-3 (mouse) sLDNFFAKRDKKKKK K15
CDV-3 (rat) sLDNFFAkRDKKKKK K15-ac
K15-ub
sLDNFFAkRDKKKKK
0 3
CDV-3 (human) sLDNFFAkRDKKKKK K15-ub
CDV-3 iso2 (human) SLDNFFAKRDKKKKK K15
CDV-3 (mouse) sLDNFFAKRDKKKKK K15
CDV-3 (rat) sLDNFFAKRDKKKKK K15
R24-m2
DKKKKKErsNRAAsA
0 1
CDV-3 (human) DKKKKKErsNRAAsA R24-m2
CDV-3 iso2 (human) DKKKKKERSNRAASA R24
CDV-3 (mouse) DKKKKKERSSRAANA R24
CDV-3 (rat) DKKKKKERSSRAANA R24
S25-p
KKKKKErsNRAAsAA
0 1
CDV-3 (human) KKKKKErsNRAAsAA S25-p
CDV-3 iso2 (human) KKKKKERSNRAASAA S25
CDV-3 (mouse) KKKKKERSSRAANAA S25
CDV-3 (rat) KKKKKERSSRAANAA S25
S30-p
ErsNRAAsAAGAAGs
0 5
CDV-3 (human) ErsNRAAsAAGAAGs S30-p
CDV-3 iso2 (human) ERSNRAASAAGAAGS S30
CDV-3 (mouse) ERSSRAANAASGAGG N30
CDV-3 (rat) ERSSRAANAASGAGG N30
S37-p
sAAGAAGsAGGSsGA
0 1
CDV-3 (human) sAAGAAGsAGGSsGA S37-p
CDV-3 iso2 (human) SAAGAAGSAGGSSGA S37
CDV-3 (mouse) AASGAGGSSAAAGSR S38
CDV-3 (rat) AASGAGGSSAAAGsR S38
-
gap
0 1
CDV-3 (human) gap -
CDV-3 iso2 (human) gap -
CDV-3 (mouse) GSSAAAGSRPGDGGs S44
CDV-3 (rat) GSSAAAGsRPGDGGs S44-p
S41
AAGsAGGSsGAAGAA
0 5
CDV-3 (human) AAGsAGGSsGAAGAA S41
CDV-3 iso2 (human) AAGSAGGSSGAAGAA S41
CDV-3 (mouse) SRPGDGGsLGsGARs S51-p
CDV-3 (rat) sRPGDGGsLGsGARs S51-p
S42-p
AGsAGGSsGAAGAAG
0 4
CDV-3 (human) AGsAGGSsGAAGAAG S42-p
CDV-3 iso2 (human) AGSAGGSSGAAGAAG S42
CDV-3 (mouse) GDGGsLGsGARsGDG S54-p
CDV-3 (rat) GDGGsLGsGARsGDG S54-p
G46
GGSsGAAGAAGGGAG
0 2
CDV-3 (human) GGSsGAAGAAGGGAG G46
CDV-3 iso2 (human) GGSSGAAGAAGGGAG G46
CDV-3 (mouse) sLGsGARsGDGGsLG S58-p
CDV-3 (rat) sLGsGARsGDGGsSG S58-p
G51
AAGAAGGGAGAGtRP
0 6
CDV-3 (human) AAGAAGGGAGAGtRP G51
CDV-3 iso2 (human) AAGAAGGGAGAGTRP G51
CDV-3 (mouse) ARsGDGGsLGSGsRS S63-p
CDV-3 (rat) ARsGDGGsSGSGARS S63-p
T56-p
GGGAGAGtRPGDGGT
0 2
CDV-3 (human) GGGAGAGtRPGDGGT T56-p
CDV-3 iso2 (human) GGGAGAGTRPGDGGT T56
CDV-3 (mouse) GGsLGSGsRSGDGGS S68-p
CDV-3 (rat) GGsSGSGARSGDGGS A68
-
gap
0 2
CDV-3 (human) gap -
CDV-3 iso2 (human) gap -
CDV-3 (mouse) GDGGSSRsGDGGsAG S90-p
CDV-3 (rat) GDGGTSRSGDGGSAG S90
G70
TASAGAAGPGAATKA
0 2
CDV-3 (human) TASAGAAGPGAATKA G70
CDV-3 iso2 (human) TASAGAAGPGAATKA G70
CDV-3 (mouse) SRsGDGGsAGPAGKA S95-p
CDV-3 (rat) SRSGDGGSAGPGGkA S95
K76
AGPGAATKAVtkDED
0 1
CDV-3 (human) AGPGAATKAVtkDED K76
CDV-3 iso2 (human) AGPGAATKAVTKDED K76
CDV-3 (mouse) GsAGPAGKAITKDEN K101
CDV-3 (rat) GSAGPGGkAITkDEN K101-ac
T79-p
GAATKAVtkDEDEWK
0 1
CDV-3 (human) GAATKAVtkDEDEWK T79-p
CDV-3 iso2 (human) GAATKAVTKDEDEWK T79
CDV-3 (mouse) GPAGKAITKDENEWK T104
CDV-3 (rat) GPGGkAITkDENEWk T104
K80-ac
AATKAVtkDEDEWKE
0 2
CDV-3 (human) AATKAVtkDEDEWKE K80-ac
CDV-3 iso2 (human) AATKAVTKDEDEWKE K80
CDV-3 (mouse) PAGKAITKDENEWKE K105
CDV-3 (rat) PGGkAITkDENEWkE K105-ac
K86
tkDEDEWKELEQkEV
0 1
CDV-3 (human) tkDEDEWKELEQkEV K86
CDV-3 iso2 (human) TKDEDEWKELEQKEV K86
CDV-3 (mouse) TKDENEWKEFEQREV K111
CDV-3 (rat) TkDENEWkEFEQKEV K111-ac
K91-ub
EWKELEQkEVDysGL
0 1
CDV-3 (human) EWKELEQkEVDysGL K91-ub
CDV-3 iso2 (human) EWKELEQKEVDYSGL K91
CDV-3 (mouse) EWKEFEQREVDySGL R116
CDV-3 (rat) EWkEFEQKEVDYSGL K116
Y95-p
LEQkEVDysGLRVQA
Upstream
1 211
Treatment
  • Su11274
CDV-3 (human) LEQkEVDysGLRVQA Y95-p
CDV-3 iso2 (human) LEQKEVDYSGLRVQA Y95
CDV-3 (mouse) FEQREVDySGLRVQA Y120-p
CDV-3 (rat) FEQKEVDYSGLRVQA Y120
S96-p
EQkEVDysGLRVQAM
0 8
CDV-3 (human) EQkEVDysGLRVQAM S96-p
CDV-3 iso2 (human) EQKEVDYSGLRVQAM S96
CDV-3 (mouse) EQREVDySGLRVQAM S121
CDV-3 (rat) EQKEVDYSGLRVQAM S121
S106-p
RVQAMQIssEKEEDD
Upstream
0 10
Treatment
  • angiotensin_2
  • nocodazole
CDV-3 (human) RVQAMQIssEKEEDD S106-p
CDV-3 iso2 (human) RVQAMQISSEKEEDD S106
CDV-3 (mouse) gap -
CDV-3 (rat) gap -
S107-p
VQAMQIssEKEEDDN
Upstream
0 25
Treatment
  • angiotensin_2
  • dasatinib
  • EGF
  • nocodazole
view more >
CDV-3 (human) VQAMQIssEKEEDDN S107-p
CDV-3 iso2 (human) VQAMQISSEKEEDDN S107
CDV-3 (mouse) RVQAMQIsEKEDDDN S131-p
CDV-3 (rat) RVQAMQIsEKEDDDN S131-p
G131
WEEGGGGGGGMEksS
0 5
CDV-3 (human) WEEGGGGGGGMEksS G131
CDV-3 iso2 (human) WEEGGGGGGGMEKSS G131
CDV-3 (mouse) WEEGGGGsGAEKSSG S155-p
CDV-3 (rat) WEEGGGGsGAEKSSG S155-p
K136-ub
GGGGGMEksSGPWNK
0 1
CDV-3 (human) GGGGGMEksSGPWNK K136-ub
CDV-3 iso2 (human) GGGGGMEKSSGPWNK K136
CDV-3 (mouse) GGGsGAEKSSGPWNK K159
CDV-3 (rat) GGGsGAEKSSGPWNK K159
S137-p
GGGGMEksSGPWNKT
0 1
CDV-3 (human) GGGGMEksSGPWNKT S137-p
CDV-3 iso2 (human) GGGGMEKSSGPWNKT S137
CDV-3 (mouse) GGsGAEKSSGPWNKT S160
CDV-3 (rat) GGsGAEKSSGPWNKT S160
I155
QAPPAPVIVTEtPEP
0 1
CDV-3 (human) QAPPAPVIVTEtPEP I155
CDV-3 iso2 (human) QAPPAPVIVTETPEP I155
CDV-3 (mouse) QAPPAPVtVTEtPEP T178-gl
CDV-3 (rat) QAPPAPVTVTETPEP T178
T159-p
APVIVTEtPEPAMts
0 4
CDV-3 (human) APVIVTEtPEPAMts T159-p
CDV-3 iso2 (human) APVIVTETPEPAMTS T159
CDV-3 (mouse) APVtVTEtPEPAMPS T182-p
CDV-3 (rat) APVTVTETPEPAMPS T182
T165-p
EtPEPAMtsGVyRPP
0 7
CDV-3 (human) EtPEPAMtsGVyRPP T165-p
CDV-3 iso2 (human) ETPEPAMTSGVYRPP T165
CDV-3 (mouse) EtPEPAMPSGVYRPP P188
CDV-3 (rat) ETPEPAMPSGVYRPP P188
S166-p
tPEPAMtsGVyRPPG
0 7
CDV-3 (human) tPEPAMtsGVyRPPG S166-p
CDV-3 iso2 (human) TPEPAMTSGVYRPPG S166
CDV-3 (mouse) tPEPAMPSGVYRPPG S189
CDV-3 (rat) TPEPAMPSGVYRPPG S189
Y169-p
PAMtsGVyRPPGARL
Upstream
0 57
Treatment
  • Su11274
CDV-3 (human) PAMtsGVyRPPGARL Y169-p
CDV-3 iso2 (human) PAMTSGVYRPPGARL Y169
CDV-3 (mouse) PAMPSGVYRPPGARL Y192
CDV-3 (rat) PAMPSGVYRPPGARL Y192
T177-p
RPPGARLtttRktPQ
0 2
CDV-3 (human) RPPGARLtttRktPQ T177-p
CDV-3 iso2 (human) RPPGARLTTTRKTPQ T177
CDV-3 (mouse) RPPGARLTTTRKtPQ T200
CDV-3 (rat) RPPGARLTTTRKTPQ T200
T178-p
PPGARLtttRktPQG
0 2
CDV-3 (human) PPGARLtttRktPQG T178-p
CDV-3 iso2 (human) PPGARLTTTRKTPQG T178
CDV-3 (mouse) PPGARLTTTRKtPQG T201
CDV-3 (rat) PPGARLTTTRKTPQG T201
T179-p
PGARLtttRktPQGP
0 1
CDV-3 (human) PGARLtttRktPQGP T179-p
CDV-3 iso2 (human) PGARLTTTRKTPQGP T179
CDV-3 (mouse) PGARLTTTRKtPQGP T202
CDV-3 (rat) PGARLTTTRKTPQGP T202
K181-ub
ARLtttRktPQGPPE
0 5
CDV-3 (human) ARLtttRktPQGPPE K181-ub
CDV-3 iso2 (human) ARLTTTRKTPQGPPE K181
CDV-3 (mouse) ARLTTTRKtPQGPPE K204
CDV-3 (rat) ARLTTTRKTPQGPPE K204
T182-p
RLtttRktPQGPPEI
Upstream
0 66
Treatment
  • nocodazole
CDV-3 (human) RLtttRktPQGPPEI T182-p
CDV-3 iso2 (human) RLTTTRKTPQGPPEI T182
CDV-3 (mouse) RLTTTRKtPQGPPEI T205-p
CDV-3 (rat) RLTTTRKTPQGPPEI T205
Y190-p
PQGPPEIysDtQFPs
Upstream
0 881
Regulatory protein:
  • FGFR1 (human)
Treatment
  • ephrin_B1
  • ephrin_B2
  • FGF1
  • FGF2
  • HGF
  • PD173074
view more >
CDV-3 (human) PQGPPEIysDtQFPs Y190-p
CDV-3 iso2 (human) PQGPPEIYSDTQFPS Y190
CDV-3 (mouse) PQGPPEIysDTQFPs Y213-p
CDV-3 (rat) PQGPPEIySDTQFPS Y213-p
S191-p
QGPPEIysDtQFPsL
0 79
CDV-3 (human) QGPPEIysDtQFPsL S191-p
CDV-3 iso2 (human) QGPPEIYSDTQFPSL S191
CDV-3 (mouse) QGPPEIysDTQFPsL S214-p
CDV-3 (rat) QGPPEIySDTQFPSL S214
T193-p
PPEIysDtQFPsLQS
0 3
CDV-3 (human) PPEIysDtQFPsLQS T193-p
CDV-3 iso2 (human) PPEIYSDTQFPSLQS T193
CDV-3 (mouse) PPEIysDTQFPsLQS T216
CDV-3 (rat) PPEIySDTQFPSLQS T216
S197-p
ysDtQFPsLQSTAkH
Upstream
0 33
Treatment
  • ischemia
CDV-3 (human) ysDtQFPsLQSTAkH S197-p
CDV-3 iso2 (human) YSDTQFPSLQSTAKH S197
CDV-3 (mouse) ysDTQFPsLQSTAKH S220-p
CDV-3 (rat) ySDTQFPSLQSTAkH S220
K203
PsLQSTAKHVESRKD
0 1
CDV-3 (human) PsLQSTAKHVESRKD K203
CDV-3 iso2 (human) PSLQSTAKHVESRNR K203
CDV-3 (mouse) PsLQSTAKHVESRKD K226
CDV-3 (rat) PSLQSTAkHVESRNR K226-ac
K203-ub
PsLQSTAkHVESRKD
0 4
CDV-3 (human) PsLQSTAkHVESRKD K203-ub
CDV-3 iso2 (human) PSLQSTAKHVESRNR K203
CDV-3 (mouse) PsLQSTAKHVESRKD K226
CDV-3 (rat) PSLQSTAKHVESRNR K226
S216-p
KDKEMEKsFEVVRHK
0 5
CDV-3 (human) KDKEMEKsFEVVRHK S216-p
CDV-3 iso2 (human) gap -
CDV-3 (mouse) KDKEMEKsFEVVRHK S239-p
CDV-3 (rat) gap -
Y244-p
KLQLDNQyAVLENQk
Upstream
0 512
Treatment
  • ephrin_B1
  • ephrin_B2
  • erlotinib
  • gefitinib
  • HGF
  • PD173074
  • Su11274
view more >
CDV-3 (human) KLQLDNQyAVLENQk Y244-p
CDV-3 iso2 (human) gap -
CDV-3 (mouse) KLQLDNQyAVLENQK Y267-p
CDV-3 (rat) gap -
K251-ub
yAVLENQkssHsQyN
0 6
CDV-3 (human) yAVLENQkssHsQyN K251-ub
CDV-3 iso2 (human) gap -
CDV-3 (mouse) yAVLENQKYSHTQYS K274
CDV-3 (rat) gap -
S252-p
AVLENQkssHsQyN_
0 1
CDV-3 (human) AVLENQkssHsQyN_ S252-p
CDV-3 iso2 (human) gap -
CDV-3 (mouse) AVLENQKYSHTQYS_ Y275
CDV-3 (rat) gap -
S253-p
VLENQkssHsQyN__
0 2
CDV-3 (human) VLENQkssHsQyN__ S253-p
CDV-3 iso2 (human) gap -
CDV-3 (mouse) VLENQKYSHTQYS__ S276
CDV-3 (rat) gap -
S255-p
ENQkssHsQyN____
0 1
CDV-3 (human) ENQkssHsQyN____ S255-p
CDV-3 iso2 (human) gap -
CDV-3 (mouse) ENQKYSHTQYS____ T278
CDV-3 (rat) gap -
Y257-p
QkssHsQyN______
0 15
CDV-3 (human) QkssHsQyN______ Y257-p
CDV-3 iso2 (human) gap -
CDV-3 (mouse) QKYSHTQYS______ Y280
CDV-3 (rat) gap -